Effects of new class III antiarrhythmic drug niferidil on electrical activity in murine ventricular myocardium and their ionic mechanisms

被引:0
作者
Denis V. Abramochkin
Vladislav S. Kuzmin
Leonid V. Rosenshtraukh
机构
[1] Lomonosov Moscow State University,Department of Human and Animal Physiology
[2] Pirogov Russian National Research Medical University,Department of Physiology
[3] Institute of Experimental Cardiology,undefined
来源
Naunyn-Schmiedeberg's Archives of Pharmacology | 2015年 / 388卷
关键词
Antiarrhythmic drug; Atrial fibrillation; Action potential; Ionic currents; Atrial-selective;
D O I
暂无
中图分类号
学科分类号
摘要
A new class III antiarrhythmic drug niferidil has been recently introduced as a highly effective therapy cure for cases of persistent atrial fibrillation, but ionic mechanisms of its action are still unknown. Effects of niferidil on action potential (AP) waveform and major ionic currents were studied in mouse ventricular myocardium. APs were recorded with glass microelectrodes in multicellular preparations of right ventricular wall. Whole-cell patch-clamp technique was used to measure K+, Ca2+, and Na+ currents in isolated mouse ventricular myocytes. While 10−7 M niferidil failed to alter the AP configuration, 10−6 M tended to prolong APs (by 12.05 ± 1.8 % at 50 % of repolarization) and 10−5 M induced significant slowing of repolarization (32.1 ± 4.9 % at 50 % of repolarization). Among the potassium currents responsible for AP repolarization phase, IK1 was found to be almost insensitive to niferidil. Ito demonstrated low sensitivity to niferidil with IC50 = 2.03 × 10−4 M. IKur, which was previously hypothesized to be the main target of the drug, was more sensitive with IC50 = 6 × 10−5 M. However, sustained delayed rectifier potassium current Iss was inhibited with even lower IC50 = 2.8 × 10−5 M. Therefore, suppression of Iss and, second, IKur by niferidil seems to underlie the AP prolongation in mouse ventricular tissue. Niferidil also produced a modest decrease in ICaL peak amplitude (IC50≈10−4 M), but failed to alter INa significantly. Niferidil prolongs APs in mouse ventricular myocardium mainly by inhibiting Iss and IKur K+ currents, but not exclusively IKur, as was proposed earlier. Further investigations are required to reveal the mechanisms of niferidil action in human myocardium, where IKr is strongly expressed instead of Iss.
引用
收藏
页码:1105 / 1112
页数:7
相关论文
共 27 条
  • [21] ELECTROPHYSIOLOGIC ACTIVITY AND ANTIARRHYTHMIC EFFICACY OF CK-3579, A NEW CLASS-III ANTIARRHYTHMIC AGENT WITH BETA-ADRENERGIC BLOCKING PROPERTIES
    ARGENTIERI, TM
    TROY, HH
    CARROLL, MS
    DOROSHUK, CM
    SULLIVAN, ME
    JOURNAL OF CARDIOVASCULAR PHARMACOLOGY, 1993, 21 (04) : 647 - 655
  • [22] Effects of class I and III antiarrhythmic drugs on ventricular tachycardia-interrupting critical paced cycle length with rapid pacing
    Naitoh, N
    Washizuka, T
    Takahashi, K
    Aizawa, Y
    JAPANESE CIRCULATION JOURNAL-ENGLISH EDITION, 1998, 62 (04): : 267 - 273
  • [23] Effects of Landiolol, an Ultra-Short-Acting β1-Selective Blocker, on Electrical Storm Refractory to Class III Antiarrhythmic Drugs
    Miwa, Yosuke
    Ikeda, Takanori
    Mera, Hisaaki
    Miyakoshi, Mutsumi
    Hoshida, Kyoko
    Yanagisawa, Ryoji
    Ishiguro, Haruhisa
    Tsukada, Takehiro
    Abe, Atsuko
    Yusu, Satoru
    Yoshino, Hideaki
    CIRCULATION JOURNAL, 2010, 74 (05) : 856 - 863
  • [24] Differential effects of class I antiarrhythmic drugs on the guinea pig pulmonary vein myocardium: Inhibition of automatic activity correlates with blockade of a diastolic sodium current component
    Irie, Masahiko
    Hiiro, Haruhito
    Kato, Shu
    Kuramochi, Mizuki
    Hamaguchi, Shogo
    Namekata, Iyuki
    Tanaka, Hikaru
    JOURNAL OF PHARMACOLOGICAL SCIENCES, 2020, 143 (04) : 325 - 329
  • [25] Analysis of Arrhythmogenic profile in a canine model of chronic atrioventricular block by comparing in vitro effects of the class III antiarrhythmic drug nifekalant on the ventricular action potential indices between normal heart and atrioventricular block heart
    Takahara, Akira
    Nakamura, Hideki
    Nouchi, Hideaki
    Tamura, Takeshi
    Tanaka, Toshikazu
    Shimada, Hideaki
    Tamura, Miku
    Tsuruoka, Noriko
    Takeda, Kentaro
    Tanaka, Hikaru
    Shigenobu, Koki
    Hashimoto, Keitaro
    Sugiyama, Atsushi
    JOURNAL OF PHARMACOLOGICAL SCIENCES, 2007, 103 (02) : 181 - 188
  • [26] Electrophysiologic effects of SD-3212, a new class I antiarrhythmic drug, on canine atrial flutter and atrial action-potential characteristics
    Fujiki, A
    Tani, M
    Hayashi, H
    Mizumaki, K
    Inoue, H
    Uemura, H
    Nakaya, H
    JOURNAL OF CARDIOVASCULAR PHARMACOLOGY, 1997, 29 (04) : 471 - 475
  • [27] ELECTROPHYSIOLOGIC EFFECTS OF A NEW CLASS-III ANTIARRHYTHMIC AGENT, E-4031, ON ATRIAL-FLUTTER, ATRIAL REFRACTORINESS, AND CONDUCTION DELAY IN A CANINE STERILE PERICARDITIS MODEL
    SHIMIZU, A
    KAIBARA, M
    CENTURION, OA
    KAPUKU, G
    HIRATA, T
    FUKATANI, M
    YANO, K
    HASHIBA, K
    JOURNAL OF CARDIOVASCULAR PHARMACOLOGY, 1993, 21 (04) : 656 - 662